NCT02805556View on ClinicalTrials.gov

Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

March 15, 2016

Primary Completion Date

May 5, 2016

Study Completion Date

May 5, 2016

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

BMS-663068

Single oral dose of BMS-663068

DRUG

BMS-626529

Single intravenous dose of \[13C\]BMS 626529

Trial Locations (1)

BT 28 2 RF

GSK Investigational Site, Lisburn

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY